Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Emergent Biosolutions reports decreased revenue in 2010 first quarter

Emergent BioSolutions Inc. announced today its financial results for the first quarter ended March 31, 2010. For the first quarter 2010, total revenues were $46.8 million as compared to $64.5 million in 2009, and net income was $2.5 million, or $0.08 per share, as compared to $11.1 million, or $0.37 per share, in 2009.

6 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.

3 May 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended March 31, 2010.

3 May 2010

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.

3 May 2010

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute to conduct an investigator sponsored Phase II clinical trial.

30 Apr 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.

29 Apr 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Pain Therapeutics, Inc., a biopharmaceutical company, today reported first quarter 2010 financial results. Net loss for Q1 2010 was $1.0 million, or $0.02 per share, compared to a net loss of $1.8 million, or $0.04 per share, for Q1 2009.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

MorphoSys AG reports Q1 results for 2010

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the three months ending March 31, 2010 according to International Financial Reporting Standards (IFRS).

27 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent. This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn's disease as a lead indication.

26 Apr 2010

National Securities, MD Becker Partners to host SCIENCE program

National Securities Corporation and MD Becker Partners will host their inaugural Stem Cell Investor & Executive Networking Conference Event on June 1, 2010, from 11:00am to 3:00pm (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.

26 Apr 2010

Monoclonal Antibody News and Research

Further Reading

Emergent Biosolutions reports decreased revenue in 2010 first quarter

Roche announces Health Canada approval for ACTEMRA to treat RA

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

REGN reports net loss of $30.5M for first-quarter 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

MorphoSys AG reports Q1 results for 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

National Securities, MD Becker Partners to host SCIENCE program

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News